CAI Stock Recent News

Live Updates Live Coverage Has Ended IPO Soars 12:56 pm by Gerelyn Terzo The markets embraced healthcare newcomer Caris Life Sciences (Nasdaq: CAI) today, marking its debut on the Nasdaq. After pricing its initial public offering at $21 per share, Caris Life skyrocketed, rising over 32% to hit $27.85 per share. The company is at the forefront of medical innovation, harnessing AI algorithms in blood tests to diagnose early detection of diseases like breast cancer. The SPY ETF is now up 0.35%. Rising Stocks 11:23 am by Gerelyn Terzo Hasbro (Nasdaq: HAS) shares are up 1.3% today. The toymaker is undertaking a restructuring, resulting in the layoff of 3% of its workforce, a move attributed to the impact of tariffs. Circle (NYSE: CRCL) is surging 16% today, buoyed by the passage of stablecoin-friendly legislation in Congress. Magnificent 7 stock Amazon (Nasdaq: AMZN) is up 0.88% after CEO Andy Jassy projected that artificial intelligence will reshape the corporate workforce in the not-too-d

Live Updates Live Coverage Updates appear automatically as they are published. Today's IPO Receives Warm Welcome 12:53 pm by Gerelyn Terzo The markets rolled out the welcome mat for healthcare stock Caris Life Sciences (Nasdaq: CAI) today, which makes its debut on the Nasdaq. After pricing the IPO at $21 per share, Caris Life has climbed over 32% to $27.85 per share. Caris Life uses AI algorithms in blood tests to diagnose early detection of diseases like breast cancer. The Nasdaq Composite is up 0.47%. Market Gainers 11:17 am by Gerelyn Terzo Hasbro (Nasdaq: HAS) stock is up 1.3% today. The toymaker announced a restructuring in which it is laying off 3% of its workforce due to the impact of the tariffs. Circle (NYSE: CRCL) is soaring 16% today on the heels of stablecoin-friendly legislation that was passed by Congress. Amazon (Nasdaq: AMZN) is up 0.88% today after CEO Andy Jassy forecast that AI would replace more of the corporate workforce in the not-too-distant future as the e-

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.

Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.

Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new listings in 2025.

David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology to help diagnose and treat cancer,

Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market.

It's looking like it could be a fairly hot June for IPOs as a handful of firms debut on the public markets for the very first time.

Caris Life Sciences has filed to raise $100 million in a U.S. IPO, although the final amount may be higher. CAI operates in the precision medicine information market for the treatment of cancer and wants to ultimately expand into other disease conditions. The company faces significant competition, high debt, payer concentration risk.